The Europe Human Milk Oligosaccharides Market is expected to reach USD 210.6 million by 2031, growing at a CAGR of 11.1% during 2026-2033.
The Germany and UK led the Europe Human Milk Oligosaccharides Market by Country with a market share of 21% and 17.1% in 2025.The Spain market is expected to witness a CAGR of 12.5% during throughout the forecast period.
The Europe Human Milk Oligosaccharides (HMO) Market originated from increasing scientific understanding of HMOs as critical bioactive compounds naturally present in human breast milk that support infant immunity, gut microbiota development, and overall health. Early market development was driven by advances in analytical technologies and biotechnology that enabled the identification, characterization, and commercial production of HMOs through microbial fermentation and enzymatic synthesis.
The market is driven by increasing demand for premium infant nutrition products, rising awareness regarding microbiome health, expanding applications of HMOs in functional nutrition, and continuous advancements in fermentation technologies. Manufacturers are investing in research and development to improve production efficiency, expand HMO portfolios, and develop innovative formulations targeting digestive health, immune support, and cognitive development. Additionally, stringent European regulatory standards continue to enhance consumer confidence and support market growth.
Leading companies focus on technological innovation, strategic collaborations, production capacity expansion, and regulatory compliance. Investments in advanced fermentation technologies, analytical capabilities, and sustainable manufacturing processes continue to strengthen competitiveness and accelerate commercialization across Europe.
Application Outlook
Based on Application, the Europe Human Milk Oligosaccharides Market is segmented into Infant Formula, Dietary Supplements, Food & Beverages, and Pharmaceuticals. The Infant Formula market dominated the Europe Human Milk Oligosaccharides Market by Application in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 160.4 million by 2033, growing at a CAGR of 10.7 % during the forecast period. The Dietary Supplements market is expected to witness a CAGR of 11.7% during 2026-2033.
The Infant Formula segment garnered the highest revenue share in the market owing to increasing demand for advanced infant nutrition products that closely replicate the functional benefits of breast milk. Dietary Supplements also recorded a significant share due to growing consumer interest in gut health, immunity, and microbiome-focused nutrition. Meanwhile, Food & Beverages and Pharmaceuticals continue to gain traction as manufacturers increasingly incorporate HMOs into functional nutrition products and therapeutic applications.
Type Outlook
Based on Type, the Europe Human Milk Oligosaccharides Market is segmented into 2’FL, LNnT, 3’FL, 6’SL, 3’SL, LNT, and DFL. The 2’FL market dominated the Europe Human Milk Oligosaccharides Market by Type in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 85.7 million by 2033, growing at a CAGR of 9.9 % during the forecast period. The LNnT market is expected to witness a CAGR of 10.1% during 2026-2033.
The 2’FL segment garnered the highest revenue share in the market owing to extensive clinical validation, strong regulatory acceptance, and widespread adoption in infant nutrition products. LNnT also recorded a significant share due to increasing use in premium infant formula formulations. Meanwhile, 3’FL, 6’SL, 3’SL, LNT, and DFL continue to witness growing adoption as manufacturers seek to replicate the complexity and nutritional functionality of human breast milk.
Country Outlook
Based on Country, the Europe Human Milk Oligosaccharides Market is segmented into Germany, United Kingdom, France, Russia, Spain, Italy, and Rest of Europe. The Germany market dominated the Europe Human Milk Oligosaccharides Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 40.8 million by 2031, growing at a CAGR of 9.5 % during the forecast period. The UK market is expected to witness a CAGR of 10% during 2026-2033.
Germany acquired a major share of the market owing to its strong biotechnology industry, advanced infant nutrition sector, and significant investments in HMO research and production technologies. The United Kingdom and France also recorded notable market shares supported by increasing adoption of premium infant nutrition products, strong regulatory frameworks, and expanding investments in biotechnology innovation.
List of Key Companies Profiled
By Application
The Germany and UK led the Europe Human Milk Oligosaccharides Market by Country with a market share of 21% and 17.1% in 2025.The Spain market is expected to witness a CAGR of 12.5% during throughout the forecast period.
The Europe Human Milk Oligosaccharides (HMO) Market originated from increasing scientific understanding of HMOs as critical bioactive compounds naturally present in human breast milk that support infant immunity, gut microbiota development, and overall health. Early market development was driven by advances in analytical technologies and biotechnology that enabled the identification, characterization, and commercial production of HMOs through microbial fermentation and enzymatic synthesis.
The market is driven by increasing demand for premium infant nutrition products, rising awareness regarding microbiome health, expanding applications of HMOs in functional nutrition, and continuous advancements in fermentation technologies. Manufacturers are investing in research and development to improve production efficiency, expand HMO portfolios, and develop innovative formulations targeting digestive health, immune support, and cognitive development. Additionally, stringent European regulatory standards continue to enhance consumer confidence and support market growth.
Leading companies focus on technological innovation, strategic collaborations, production capacity expansion, and regulatory compliance. Investments in advanced fermentation technologies, analytical capabilities, and sustainable manufacturing processes continue to strengthen competitiveness and accelerate commercialization across Europe.
Application Outlook
Based on Application, the Europe Human Milk Oligosaccharides Market is segmented into Infant Formula, Dietary Supplements, Food & Beverages, and Pharmaceuticals. The Infant Formula market dominated the Europe Human Milk Oligosaccharides Market by Application in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 160.4 million by 2033, growing at a CAGR of 10.7 % during the forecast period. The Dietary Supplements market is expected to witness a CAGR of 11.7% during 2026-2033.
The Infant Formula segment garnered the highest revenue share in the market owing to increasing demand for advanced infant nutrition products that closely replicate the functional benefits of breast milk. Dietary Supplements also recorded a significant share due to growing consumer interest in gut health, immunity, and microbiome-focused nutrition. Meanwhile, Food & Beverages and Pharmaceuticals continue to gain traction as manufacturers increasingly incorporate HMOs into functional nutrition products and therapeutic applications.
Type Outlook
Based on Type, the Europe Human Milk Oligosaccharides Market is segmented into 2’FL, LNnT, 3’FL, 6’SL, 3’SL, LNT, and DFL. The 2’FL market dominated the Europe Human Milk Oligosaccharides Market by Type in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 85.7 million by 2033, growing at a CAGR of 9.9 % during the forecast period. The LNnT market is expected to witness a CAGR of 10.1% during 2026-2033.
The 2’FL segment garnered the highest revenue share in the market owing to extensive clinical validation, strong regulatory acceptance, and widespread adoption in infant nutrition products. LNnT also recorded a significant share due to increasing use in premium infant formula formulations. Meanwhile, 3’FL, 6’SL, 3’SL, LNT, and DFL continue to witness growing adoption as manufacturers seek to replicate the complexity and nutritional functionality of human breast milk.
Country Outlook
Based on Country, the Europe Human Milk Oligosaccharides Market is segmented into Germany, United Kingdom, France, Russia, Spain, Italy, and Rest of Europe. The Germany market dominated the Europe Human Milk Oligosaccharides Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 40.8 million by 2031, growing at a CAGR of 9.5 % during the forecast period. The UK market is expected to witness a CAGR of 10% during 2026-2033.
Germany acquired a major share of the market owing to its strong biotechnology industry, advanced infant nutrition sector, and significant investments in HMO research and production technologies. The United Kingdom and France also recorded notable market shares supported by increasing adoption of premium infant nutrition products, strong regulatory frameworks, and expanding investments in biotechnology innovation.
List of Key Companies Profiled
- DSM-Firmenich AG
- International Flavors & Fragrances Inc.
- BASF SE
- Abbott Laboratories
- Nestlé S.A.
- FrieslandCampina C.V.
- Novonesis A/S
- Inbiose NV
- KYOWA HAKKO BIO Co., Ltd. (Kirin Holdings Co., Ltd.)
- ELICITYL S.A.
By Application
- Infant Formula
- Dietary Supplements
- Food & Beverages
- Pharmaceuticals
- 2’FL
- LNnT
- 3’FL
- 6’SL
- 3’SL
- LNT
- DFL
- Germany
- United Kingdom
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Europe Market1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By Application
1.4.1 Infant Formula
1.4.2 Dietary Supplements
1.4.3 Food & Beverages
1.4.4 Pharmaceuticals
1.5 Segmentation By Type
1.5.1 ’FL
1.5.2 LNnT
1.5.3 ’FL
1.5.4 ’SL
1.5.5 ’SL
1.5.6 LNT
1.5.7 DFL
1.6 Segmentation By Country
1.6.1 Germany
1.6.1.1 Segmentation By Application
1.6.1.1.1 Infant Formula
1.6.1.1.2 Dietary Supplements
1.6.1.1.3 Food & Beverages
1.6.1.1.4 Pharmaceuticals
1.6.1.2 Segmentation By Type
1.6.1.2.1 ’FL
1.6.1.2.2 LNnT
1.6.1.2.3 ’FL
1.6.1.2.4 ’SL
1.6.1.2.5 ’SL
1.6.1.2.6 LNT
1.6.1.2.7 DFL
1.6.2 UK
1.6.2.1 Segmentation By Application
1.6.2.1.1 Infant Formula
1.6.2.1.2 Dietary Supplements
1.6.2.1.3 Food & Beverages
1.6.2.1.4 Pharmaceuticals
1.6.2.2 Segmentation By Type
1.6.2.2.1 ’FL
1.6.2.2.2 LNnT
1.6.2.2.3 ’FL
1.6.2.2.4 ’SL
1.6.2.2.5 ’SL
1.6.2.2.6 LNT
1.6.2.2.7 DFL
1.6.3 France
1.6.3.1 Segmentation By Application
1.6.3.1.1 Infant Formula
1.6.3.1.2 Dietary Supplements
1.6.3.1.3 Food & Beverages
1.6.3.1.4 Pharmaceuticals
1.6.3.2 Segmentation By Type
1.6.3.2.1 ’FL
1.6.3.2.2 LNnT
1.6.3.2.3 ’FL
1.6.3.2.4 ’SL
1.6.3.2.5 ’SL
1.6.3.2.6 LNT
1.6.3.2.7 DFL
1.6.4 Russia
1.6.4.1 Segmentation By Application
1.6.4.1.1 Infant Formula
1.6.4.1.2 Dietary Supplements
1.6.4.1.3 Food & Beverages
1.6.4.1.4 Pharmaceuticals
1.6.4.2 Segmentation By Type
1.6.4.2.1 ’FL
1.6.4.2.2 LNnT
1.6.4.2.3 ’FL
1.6.4.2.4 ’SL
1.6.4.2.5 ’SL
1.6.4.2.6 LNT
1.6.4.2.7 DFL
1.6.5 Spain
1.6.5.1 Segmentation By Application
1.6.5.1.1 Infant Formula
1.6.5.1.2 Dietary Supplements
1.6.5.1.3 Food & Beverages
1.6.5.1.4 Pharmaceuticals
1.6.5.2 Segmentation By Type
1.6.5.2.1 ’FL
1.6.5.2.2 LNnT
1.6.5.2.3 ’FL
1.6.5.2.4 ’SL
1.6.5.2.5 ’SL
1.6.5.2.6 LNT
1.6.5.2.7 DFL
1.6.6 Italy
1.6.6.1 Segmentation By Application
1.6.6.1.1 Infant Formula
1.6.6.1.2 Dietary Supplements
1.6.6.1.3 Food & Beverages
1.6.6.1.4 Pharmaceuticals
1.6.6.2 Segmentation By Type
1.6.6.2.1 ’FL
1.6.6.2.2 LNnT
1.6.6.2.3 ’FL
1.6.6.2.4 ’SL
1.6.6.2.5 ’SL
1.6.6.2.6 LNT
1.6.6.2.7 DFL
1.6.7 Rest of Europe
1.6.7.1 Segmentation By Application
1.6.7.1.1 Infant Formula
1.6.7.1.2 Dietary Supplements
1.6.7.1.3 Food & Beverages
1.6.7.1.4 Pharmaceuticals
1.6.7.2 Segmentation By Type
1.6.7.2.1 ’FL
1.6.7.2.2 LNnT
1.6.7.2.3 ’FL
1.6.7.2.4 ’SL
1.6.7.2.5 ’SL
1.6.7.2.6 LNT
1.6.7.2.7 DFL
Chapter 2. Company Snapshot
2.1 DSM-Firmenich AG
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Novozymes A/S
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 International Flavors & Fragrances Inc.
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 BASF SE
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users
2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Abbott Laboratories
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Nestlé S.A.
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 FrieslandCampina C.V.
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 KYOWA HAKKO BIO Co., Ltd.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 Inbiose NV
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 ELICITYL S.A.
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook
Companies Mentioned
- DSM-Firmenich AG
- International Flavors & Fragrances Inc.
- BASF SE
- Abbott Laboratories
- Nestlé S.A.
- FrieslandCampina C.V.
- Novonesis A/S
- Inbiose NV
- KYOWA HAKKO BIO Co., Ltd. (Kirin Holdings Co., Ltd.)
- ELICITYL S.A.
